Inverness Terminates Thermo Fisher Contract to Resell Biosite Products | GenomeWeb

This story originally ran on Nov. 12.

Inverness Medical Innovations has terminated its contract with Thermo Fisher Scientific for the resale of Inverness' Biosite products.

The disclosure was made this week in a document filed by Thermo Fisher with the US Securities and Exchange Commission. The termination takes effect on July 1, 2010.

Inverness purchased Biosite in 2007. Among the products offered by Biosite are protein biomarker-based tests for congestive heart failure and cardiovascular diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.